Table 2.
Immune checkpoint inhibitors regimen | N (observed) | N | 25th percentile | Median (weeks) |
75th percentile |
---|---|---|---|---|---|
Nivolumab | 276 | 39 | 6.0 | 10.0 | 20 |
Atezolizumab | 54 | 8 | 5.5 | 10.0 | 12 |
Pembrolizumab | 117 | 21 | 3.0 | 8.0 | 20 |
Ipilimumab only | 17 | 4 | 13.0 | 15.5 | 30 |
2+ agents, including ipilimumab | 63 | 19 | 5.0 | 9.0 | 34 |
2+ agents, not including ipilimumab | 24 | 4 | 11.0 | 23.5 | 44 |